CN Patent

CN119213006A — 用于增强肝脏和肾脏特异性靶向的遗传序列-糖缀合物

Assigned to University of Connecticut · Expires 2024-12-27 · 1y expired

What this patent protects

公开了一种具有式(I)的遗传序列‑糖缀合物： 其中GS是遗传序列，优选地肽核酸或寡核苷酸，诸如mRNA序列、siRNA序列或DNA序列，任选地其中每个遗传序列是天然的或经修饰的，并且变量如本文所述。还公开了该遗传序列‑糖缀合物的用途，包括作为靶向包括人在内的哺乳动物的肝脏和肾脏的RNA治疗剂。

USPTO Abstract

公开了一种具有式(I)的遗传序列‑糖缀合物： 其中GS是遗传序列，优选地肽核酸或寡核苷酸，诸如mRNA序列、siRNA序列或DNA序列，任选地其中每个遗传序列是天然的或经修饰的，并且变量如本文所述。还公开了该遗传序列‑糖缀合物的用途，包括作为靶向包括人在内的哺乳动物的肝脏和肾脏的RNA治疗剂。

Drugs covered by this patent

Patent Metadata

Patent number
CN119213006A
Jurisdiction
CN
Classification
—
Expires
2024-12-27
Drug substance claim
No
Drug product claim
No
Assignee
University of Connecticut
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.